TY - JOUR
T1 - Vaccination against COVID-19 in patients with solid cancer
T2 - Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)
AU - intergroupe coopérateur de neuro-oncologie association des neuro-oncologues d'expression française (IGCNO-ANOCEF)
AU - Société Française de Chirurgie Digestive (SFCD)
AU - Société Française d'Endoscopie Digestive (SFED)
AU - Société Française de Radiothérapie Oncologique (SFRO)
AU - Société Française de Radiologie (SFR)
AU - Société Nationale Française de Colo-Proctologie (SNFCP)
AU - Société Nationale Française de Gastroentérologie (SNFGE)
AU - Thésaurus National de Cancérologie Digestive (TNCD)
AU - réseau de Groupes Coopérateurs en Oncologie (GCO)
AU - Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)
AU - Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)
AU - association de recherche sur les cancers gynecologiques-groupes d'investigateurs nationaux pour l’étude des cancers ovariens et du sein (ARCAGY-GINECO)
AU - Fédération francophone de cancérologie digestive (FFCD), groupe coopérateur multidisciplinaire en oncologie (GERCOR), groupe d'oncologie radiothérapie tête et cou-intergroupe ORL (GORTEC-Intergroupe ORL)
AU - Intergroupe Francophone de Cancérologie Thoracique (IFCT)
AU - Tougeron, David
AU - Seitz-Polski, Barbara
AU - Hentzien, Maxime
AU - Bani-Sadr, Firouze
AU - Bourhis, Jean
AU - Ducreux, Michel
AU - Gaujoux, Sébastien
AU - Gorphe, Philippe
AU - Guiu, Boris
AU - Hardy-Bessard, Anne Claire
AU - Hoang Xuan, Khê
AU - Huguet, Florence
AU - Lecomte, Thierry
AU - Lièvre, Astrid
AU - Louvet, Christophe
AU - Maggiori, Léon
AU - Mariani, Pascale
AU - Michel, Pierre
AU - Servettaz, Amélie
AU - Thariat, Juliette
AU - Westeel, Virginie
AU - Aparicio, Thomas
AU - Blay, Jean Yves
AU - Bouché, Olivier
N1 - Publisher Copyright:
© 2021 Société Française du Cancer
PY - 2021/6/1
Y1 - 2021/6/1
N2 - The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at “high risk” for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another “very high-priority” population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.
AB - The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at “high risk” for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another “very high-priority” population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.
KW - COVID-19
KW - Chemotherapy
KW - Coronavirus
KW - Radiotherapy
KW - Solid cancers
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85106302808&partnerID=8YFLogxK
U2 - 10.1016/j.bulcan.2021.03.009
DO - 10.1016/j.bulcan.2021.03.009
M3 - Review article
C2 - 33902918
AN - SCOPUS:85106302808
SN - 0007-4551
VL - 108
SP - 614
EP - 626
JO - Bulletin du Cancer
JF - Bulletin du Cancer
IS - 6
ER -